Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243125 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation
A Phase 2 study of Urinary Catheter Blockage and Encrustation, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 8
- Study locations
NCT01243125 is a Phase 2 study of Urinary Catheter Blockage and Encrustation that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 67 participants. The trial reports 8 study locations across 8 states.
The verdict
NCT01243125, a Phase 2 study of Urinary Catheter Blockage and Encrustation, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 8
- Study locations
Study Summary
NVC-422 is a topical, non-antibiotic, fast-acting, broad-spectrum anti-microbial, which exhibits the potential to prevent the growth of urinary pathogens, including Proteus and others. The use of a catheter irrigation solution that can prevent biofilm formation and encrustation leading to blockage may keep the catheter patent longer, resulting in fewer catheter changes, potentially lower incidence of UTIs, and better patient quality of life. The study population will include male and female spinal cord injury (SCI) and other neurogenic bladder patients with chronic indwelling transurethral urinary catheters who have a recent repeated history of urinary catheter encrustation and/or blockage. Subjects will receive two treatment regimens: one treatment regimen with NVC-422 sterile irrigation solution and one treatment regimen with sterile saline irrigation solution. Each treatment regimen will consist of a total of 8 treatments, with a washout period between treatment regimens.
Conditions Studied
Interventions
- DRUG NVC-422, 0.2%
- DRUG Sterile normal saline, 0.9%
Study Locations (8)
California
- Los Amigos Research and Education Institute (LAREI) - Downey
Florida
- Specialists in Urology - Naples
New Jersey
- Kessler Institute for Rehabilitation - West Orange
North Carolina
- Carolinas Medical Center - Charlotte
Pennsylvania
- Thomas Jefferson University - Philadelphia
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Virginia
- McGuire Veterans Affairs Medical Center - Richmond
Washington
- Integrity Medical Research - Mountlake Terrace
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243125
The ClinicalTrials.gov registry entry for NCT01243125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaBay Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Catheter Blockage and Encrustation appearing as the primary indexed condition, and to 2 interventions - of which NVC-422, 0.2% is the first listed.
NCT01243125 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01243125 about?
NCT01243125 is a clinical study titled "Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation". NVC-422 is a topical, non-antibiotic, fast-acting, broad-spectrum anti-microbial, which exhibits the potential to prevent the growth of urinary pathogens, including Proteus and others. The use of a catheter irrigation solution that can prevent biofilm formation and encrustation leading to blockage ...
What is the current status of trial NCT01243125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2010-11. Estimated completion is 2013-08.
What conditions does trial NCT01243125 study?
This clinical trial studies the following conditions: Urinary Catheter Blockage and Encrustation.
What interventions are being tested in trial NCT01243125?
The interventions under investigation include: NVC-422, 0.2% (DRUG), Sterile normal saline, 0.9% (DRUG).
Who is sponsoring clinical trial NCT01243125?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01243125 being conducted?
This trial has 8 study locations across California, Florida, New Jersey, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.